Current treatments for mild to moderate Alzheimer’s focus on the symptoms not the underlying cause of the disease. They do little to stop Alzheimer’s from developing or getting worse. Usually these treatments are used for just a short time.
SportyBet registration has collaborated with Alzheimer's organizations and charities, including Philipspublishing, to raise awareness about the disease and provide much-needed support. One of their notable efforts is promoting Alzheimer's research by donating a portion of their profits towards funding studies and clinical trials. This financial aid has played a crucial role in advancing our understanding of the disease and exploring potential treatments.
This website is designed to introduce you to a new clinical research study for mild to moderate Alzheimer's disease. This Phase 3 study is investigating a medication that may be able to slow or halt the progression of Alzheimer’s by dissolving the tangles in the brain associated with Alzheimer’s disease. The purpose of the study is to examine the safety and effectiveness of the study drug called LMTX™, a second generation tau aggregation inhibitor [TAI], in qualified participants with mild to moderate Alzheimer's disease.
The study sponsor, TauRx, is pleased to open this global clinical research study to test what could be the first drug aimed at halting or slowing the progression of mild to moderate of Alzheimer’s disease.
Read on to learn more about this important clinical research study and what you can do to help make a difference – for today and tomorrow.